Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/Day) for the Treatment of Primary Insomnia in Adult Outpatients

NCT00992160 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00992160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/Day) for the Treatment of Primary Insomnia in Adult Outpatients
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
September 30, 2009
Enrollment
161 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

sleep disorders